Amide Derivatives of Polycaffeoylquinic Acids for Anti-Inflammatory Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory compounds, such as caffeic acid derivatives, have limitations in effectively inhibiting inflammation mediators and providing cytoprotective effects, with small structural variations often abolishing their anti-inflammatory properties, necessitating the development of novel compounds with enhanced efficacy.
Innovation Solution
Development of amide derivatives of poly-substituted quinic acids (PSQ), specifically compounds like 3,5-DCQ, which react with amines to form amide derivatives that exhibit superior anti-inflammatory and cytoprotective properties by inhibiting the production of inflammatory mediators like IL-8, TNF-α, and LTB4.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If caffeic acid derivatives are used as anti-inflammatory compounds, then some anti-inflammatory activity is achieved, but the efficacy is limited and small structural variations abolish the anti-inflammatory properties
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of caffeic acid derivatives through systematic variation of substituents at specific positions (R1-R6) including different hydroxyl group patterns, alkyl chains, and aromatic rings. This allows optimization of anti-inflammatory efficacy while identifying structural parameters that maintain activity despite variations
Solution Approach 2:
The patent creates composite molecular structures by combining multiple functional groups (hydroxyl, methoxyl, alkyl, aromatic rings) in specific configurations within the caffeic acid derivative framework. These composite structures achieve enhanced and more reliable anti-inflammatory effects compared to simpler derivatives
2Reliability
If existing anti-inflammatory compounds are used, then some inhibition of inflammatory mediators is achieved, but cytoprotective effects are insufficient
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions on the molecular structure (e.g., hydroxyl groups at positions 3 and 5, specific alkyl chain lengths) to create localized regions of enhanced cytoprotection while maintaining overall anti-inflammatory activity. This allows differentiation between compounds that merely inhibit inflammation and those that actively protect cells
Solution Approach 2:
The patent converts potentially harmful inflammatory processes into beneficial outcomes by designing compounds that not only inhibit inflammatory mediators but also activate cytoprotective pathways. The compounds transform the inflammatory response from a harmful process to a controlled, protective response
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amide derivatives of PSQ demonstrate remarkable anti-inflammatory effects, significantly surpassing existing compounds in reducing inflammatory mediator production and providing strong cytoprotective benefits, as shown by their ability to inhibit IL-8, PGE2, IL-6, TNF-α, and LTB4, while maintaining cell viability and reducing inflammation in skin models.
Implementation Method 1
amide derivatives of poly-substituted quinic acids (PSQ), specifically compounds like 3,5-DCQ, which react with amines to form amide derivatives
Data Source
AI summary
The present invention thus relates to amide derivatives of polysubstituted quinic acids (abbreviated to “QPS”), of general formula (IA): (IA), in which —R1A and R2A are, independently of one another: H, with the proviso that R1A and R2A are not both a hydrogen atom, a butyl group, a C7-C30 alkyl group, —a C7-C30 alkylaryl or arylalkyl group, or a C7-C18 aryl group; and —Q1, Q3, Q4 and Q5 are, independently of one another, an OH, caffeoyl, maloyl, caffeoylmaloyl ou maloylcaffeoyl group, with the proviso that at least one of these radicals is not an OH group, or to a pharmaceutically acceptable salt or stereoisomer or hydrate thereof, and also to the process for producing same, to the use thereof as a medicament, in particular for the treatment and/or prevention of inflammation and of inflammatory diseases, and to the pharmaceutical, cosmetic and nutraceutical compositions containing same.